Abbott Laboratories vs Viatris
ABT and VTRS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ABT and VTRS compare
Abbott Laboratories is the larger company, worth 8.4 times as much as Viatris ($184B against $21.9B).
Abbott Laboratories grew revenue faster over the last twelve months (8.1% versus 4.4% for Viatris).
Both pay dividends: Abbott Laboratories yields 2.4% and Viatris 2.5%.
Abbott Laboratories scores higher on the StockData Score (14 against 6 for Viatris), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ABT | VTRS |
|---|---|---|
| Size and price | ||
| Market cap | $184B | $21.9B |
| Share price | $106.20 | $19.04 |
| Change, 1 year | −14.7% | 85.3% |
| Change, 5 years | −14.6% | 38.6% |
| Beta (5Y) | 0.47 | 0.87 |
| Employees | 115K | 30K |
| StockData Score | ||
| Total score | 14 (better) | 6 |
| Valuation score | 1 | 2 (better) |
| Growth score | 3 (better) | 1 |
| Performance score | 3 (better) | 0 |
| Health score | 4 (better) | 1 |
| Dividend score | 3 (better) | 2 |
| Valuation | ||
| P/E | 34.1× | – |
| P/S | 3.9× | 1.5× (better) |
| P/B | 3.6× | – |
| EV/EBITDA | 28.8× | 12.6× (better) |
| P/FCF | 23.5× | 11.2× (better) |
| FCF yield | 4.3% | 8.9% (better) |
| Fair value | $78.11 | $20.87 |
| Margin of safety | −36.0% | 8.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 8.1% (better) | 4.4% |
| Revenue growth, 5Y average | 5.1% (better) | 3.7% |
| Net income growth (TTM) | −61.2% | – |
| EPS growth (TTM) | −61.1% | – |
| EPS growth, 5Y average | 8.3% | – |
| Profitability | ||
| Gross margin | 56.6% (better) | 34.8% |
| Operating margin | 15.8% (better) | −0.59% |
| Net margin | 11.6% | – |
| FCF margin | 16.8% (better) | 13.3% |
| Return on equity | 10.7% | – |
| Return on invested capital | 7.9% | – |
| Financial health | ||
| Debt / equity | 0.64 | – |
| Net debt / EBITDA | 3.68 (better) | 4.59 |
| Interest coverage | 9.6× (better) | −0.2× |
| Current ratio | 1.38 | 1.58 (better) |
| Altman Z-score | 3.28 (better) | 1.16 |
| Piotroski F-score | 6 | – |
| Dividends and buybacks | ||
| Dividend yield | 2.4% | 2.5% (better) |
| Payout ratio | 78.5% | – |
| Years of dividend growth | 3 (better) | 0 |
| Buyback yield | 1.00% | 1.4% (better) |
| Shareholder yield | 3.4% | 3.9% (better) |
| Ownership | ||
| Held by institutions | 79.8% | 91.5% |
| Held by insiders | 0.50% | 0.36% |
| Insider net buying, 12 months | −$43.1M | −$1.1M (better) |
| Superinvestors holding | 2 | 3 (better) |
| Short interest, % of float | 0.79% | 3.7% |
Go deeper
- ABT stock overview
- ABT income statement
- ABT valuation and score
- VTRS stock overview
- VTRS income statement
- VTRS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.